UBS Group’s XTL Biopharmaceuticals XTLB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-191
| Closed | -$893 | – | 11259 |
|
|
2025
Q3 | $893 | Sell |
191
-143
| -43% | -$795 | ﹤0.01% | 9504 |
|
|
2025
Q2 | $1.52K | Buy |
+334
| New | +$1.62K | ﹤0.01% | 9604 |
|
|
2024
Q2 | – | Sell |
-1,739
| Closed | -$19.5K | – | 10195 |
|
|
2024
Q1 | $19.5K | Buy |
1,739
+1,725
| +12,321% | +$7.97K | ﹤0.01% | 6938 |
|
|
2023
Q4 | $55 | Sell |
14
-16
| -53% | -$61 | ﹤0.01% | 8985 |
|
|
2023
Q3 | $108 | Buy |
+30
| New | +$111 | ﹤0.01% | 8861 |
|
|
2023
Q1 | – | Sell |
-75
| Closed | -$363 | – | 10493 |
|
|
2022
Q4 | $363 | Buy |
+75
| New | +$372 | ﹤0.01% | 10225 |
|
|
2022
Q2 | – | Sell |
-203
| Closed | -$2K | – | 11028 |
|
|
2022
Q1 | $2K | Buy |
203
+164
| +421% | +$1.61K | ﹤0.01% | 9683 |
|
|
2021
Q4 | $0 | Sell |
39
-686
| -95% | -$9.49K | ﹤0.01% | 10780 |
|
|
2021
Q3 | $13K | Buy |
+725
| New | +$11.7K | ﹤0.01% | 7695 |
|
|
2021
Q2 | – | Sell |
-881
| Closed | -$12K | – | 9888 |
|
|
2021
Q1 | $12K | Buy |
+881
| New | +$12.1K | ﹤0.01% | 7816 |
|
|
2020
Q4 | – | Sell |
-259
| Closed | -$2K | – | 8823 |
|
|
2020
Q3 | $2K | Buy |
+259
| New | +$1.8K | ﹤0.01% | 7698 |
|
|
2020
Q1 | – | Sell |
-306
| Closed | -$2K | – | 8488 |
|
|
2019
Q4 | $2K | Sell |
306
-526
| -63% | -$2.83K | ﹤0.01% | 7856 |
|
|
2019
Q3 | $5K | Sell |
832
-50
| -6% | -$371 | ﹤0.01% | 7496 |
|
|
2019
Q2 | $7K | Sell |
882
-700
| -44% | -$6.15K | ﹤0.01% | 7256 |
|
|
2019
Q1 | $15K | Sell |
1,582
-86
| -5% | -$778 | ﹤0.01% | 6555 |
|
|
2018
Q4 | $12K | Buy |
1,668
+54
| +3% | +$507 | ﹤0.01% | 7152 |
|
|
2018
Q3 | $14K | Buy |
1,614
+1,441
| +833% | +$10.5K | ﹤0.01% | 7010 |
|
|
2018
Q2 | $1K | Sell |
173
-109
| -39% | -$818 | ﹤0.01% | 7850 |
|
|
2018
Q1 | $2K | Buy |
282
+106
| +60% | +$867 | ﹤0.01% | 7561 |
|
|
2017
Q4 | $2K | Sell |
176
-584
| -77% | -$5.6K | ﹤0.01% | 7633 |
|
|
2017
Q3 | $7K | Sell |
760
-3,317
| -81% | -$39K | ﹤0.01% | 7088 |
|
|
2017
Q2 | $52K | Buy |
4,077
+2,747
| +207% | +$29.1K | ﹤0.01% | 5614 |
|
|
2017
Q1 | $14K | Buy |
1,330
+483
| +57% | +$5.41K | ﹤0.01% | 6415 |
|
|
2016
Q4 | $11K | Buy |
+847
| New | +$12.9K | ﹤0.01% | 6873 |
|
|
2016
Q1 | – | Sell |
-18
| Closed | -$1K | – | 8266 |
|
|
2015
Q4 | $1K | Sell |
18
-67
| -79% | -$2.25K | ﹤0.01% | 8181 |
|
|
2015
Q3 | $3K | Buy |
+85
| New | +$3.13K | ﹤0.01% | 7967 |
|
|
2015
Q2 | – | Sell |
-151
| Closed | -$7K | – | 8890 |
|
|
2015
Q1 | $7K | Buy |
151
+72
| +91% | +$3.15K | ﹤0.01% | 7928 |
|
|
2014
Q4 | $3K | Buy |
+79
| New | +$3.44K | ﹤0.01% | 9282 |
|
Other funds holding XTLB
NI
GI
XT
UBS Group's XTLB Position: Q4 2025 in Review
UBS Group sold out of XTL Biopharmaceuticals (XTLB) in Q4 2025, closing a stake of 191 shares — an estimated $893 sold.
UBS Group first reported a position in XTLB in Q4 2014 and held it in 28 quarters. The position peaked at $52K in Q2 2017. 6 funds tracked by Wall St. Rank hold XTLB as of Q4 2025.
- UBS Group reported no remaining XTL Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 191 XTL Biopharmaceuticals shares in Q4 2025, an estimated $893.
- UBS Group first reported a position in XTL Biopharmaceuticals in Q4 2014 and held it in 28 quarters.
- UBS Group's XTL Biopharmaceuticals position peaked at $52K in Q2 2017.
- 6 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.